



ASX Release

16 July 2018

ZELDA THERAPEUTICS LIMITED
ACN 103 782 378

Level 26
140 St Georges Terrace,
Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
W: www.zeldatherapeutics.com

Contacts

Mr Richard Hopkins
Managing Director
+61 405 656 868
rhopkins@zeldatherapeutics.com

Mr Harry Karelis
Executive Chairman
+61 413 056 328
hkarelis@zeldatherapeutics.com

Directors

Dr Richard Hopkins
Mr Harry Karelis
Dr Stewart Washer
Ms Mara Gordon
Mr Jason Peterson

Tickers:

Australia (ASX): ZLD
USA (OTC): ZLDAF

Ordinary Shares:

755,341,934

Options:

46,000,000

1,500,000 (\$0.04 – 6/2/2020)
*4,500,000 (\$0.04 – 6/2/2020)
40,000,000 (\$0.03125 – 17/11/2021)
* subject to vesting conditions

COMMENCEMENT OF NEW MANAGING DIRECTOR

Zelda Therapeutics Ltd (ASX: ZLD, US OTC: ZLDAF, “Zelda” or the Company) is pleased to announce that Dr. Richard Hopkins has commenced as Managing Director, effective 16 July 2018.

Dr Hopkins brings extensive knowledge and experience with his established track record in drug development of novel cancer therapies and strong experience with corporate strategy, business development and intellectual property matters.

The Board looks forward to working with Dr. Hopkins to develop and grow business opportunities emerging from Zelda’s strategic focus on clinical validation of medicinal cannabis.

Dr Richard Hopkins stated:

“I am excited to be joining Zelda Therapeutics at such a key point in the Company’s development. I look forward to adding value to Zelda’s strategic direction and in particular leveraging revenue opportunities from the current clinical programmes in the fast-growing medicinal cannabis sector.”

Tim Slate **Company Secretary**

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics Ltd (“Zelda”) is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:

- A **human clinical trial programme** focused on insomnia, autism and eczema with activities in Australia, Chile and the USA.
- A **pre-clinical research programme** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

It has partnered with the world’s leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer and cognitive decline.